This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order valued at $11,849.81. The award was issued by the Defense Logistics Agency (DLA) under the SPE2DB program, a single-award indefinite delivery contract (IDC) valued up to $499,999,999 that runs through December 31, 2025. Under this IDC, DMS Pharmaceutical Group provides a comprehensive range of pharmaceutical items, from common medications to specialized drugs and medical supplies, to fulfill the recurring medical supply needs of military health facilities worldwide. This includes products such as flumazenil injections, prednisone tablets, ampicillin injections, and oncology drugs like Keytruda and Kadcyla. The contract has no set-aside designation, leveraging DMS Pharmaceutical Group's status as a woman-owned small business to secure direct awards for the DLA's pharmaceutical Prime Vendor programs supporting military medical facilities globally.
Generated 10/28/24, 9:55 AM